• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌中的肿瘤微环境:阐明治疗开发的分子途径。

The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development.

作者信息

Corn Paul G

机构信息

Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Cancer Manag Res. 2012;4:183-93. doi: 10.2147/CMAR.S32839. Epub 2012 Jul 25.

DOI:10.2147/CMAR.S32839
PMID:22904640
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3421469/
Abstract

Mechanisms leading to the development of virulent prostate cancer are not confined to the cancer epithelial cell, but also involve the tumor microenvironment. Multiple signaling pathways exist between epithelial cells, stromal cells, and the extracellular matrix to support tumor progression from the primary site to regional lymph nodes and distant metastases. Prostate cancers preferentially metastasize to the skeleton, prompting considerable research effort into understanding the unique interaction between prostate cancer epithelial cells and the bone microenvironment. This effort has led to the discovery that signaling pathways involved in normal prostate and bone development become dysregulated in cancer. These pathways stimulate excessive cell growth and neovascularization, impart more invasive properties to epithelial cells, weaken antitumor immune surveillance, and promote the emergence of castrate-resistant disease. An improved understanding of the complex relationship between cancer epithelial cells and the organ-specific microenvironments with which they interact has created a powerful opportunity to develop novel therapies.

摘要

导致侵袭性前列腺癌发生发展的机制不仅限于癌上皮细胞,还涉及肿瘤微环境。上皮细胞、基质细胞和细胞外基质之间存在多种信号通路,以支持肿瘤从原发部位进展至区域淋巴结和远处转移。前列腺癌优先转移至骨骼,这促使人们开展大量研究,以了解前列腺癌上皮细胞与骨微环境之间的独特相互作用。这些研究发现,参与正常前列腺和骨发育的信号通路在癌症中发生失调。这些通路刺激细胞过度生长和新血管形成,赋予上皮细胞更强的侵袭性,削弱抗肿瘤免疫监视,并促进去势抵抗性疾病的出现。对癌症上皮细胞与其相互作用的器官特异性微环境之间复杂关系的深入理解,为开发新疗法创造了有力契机。

相似文献

1
The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development.前列腺癌中的肿瘤微环境:阐明治疗开发的分子途径。
Cancer Manag Res. 2012;4:183-93. doi: 10.2147/CMAR.S32839. Epub 2012 Jul 25.
2
Novel therapies for metastatic castrate-resistant prostate cancer.转移性去势抵抗性前列腺癌的新型治疗方法。
J Natl Cancer Inst. 2011 Nov 16;103(22):1665-75. doi: 10.1093/jnci/djr362. Epub 2011 Sep 13.
3
Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.前列腺癌进展的分子见解:肿瘤微环境的缺失环节
J Urol. 2005 Jan;173(1):10-20. doi: 10.1097/01.ju.0000141582.15218.10.
4
The matrix environmental and cell mechanical properties regulate cell migration and contribute to the invasive phenotype of cancer cells.基质的环境和细胞力学特性调节细胞迁移,并有助于癌细胞的侵袭表型。
Rep Prog Phys. 2019 Jun;82(6):064602. doi: 10.1088/1361-6633/ab1628. Epub 2019 Apr 4.
5
Current perspectives on bone metastases in castrate-resistant prostate cancer.目前关于去势抵抗性前列腺癌骨转移的观点。
Cancer Metastasis Rev. 2018 Mar;37(1):189-196. doi: 10.1007/s10555-017-9719-4.
6
Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.前列腺癌骨转移的发病机制与治疗:靶向致死表型
J Clin Oncol. 2005 Nov 10;23(32):8232-41. doi: 10.1200/JCO.2005.03.0841.
7
Tumor-stromal interactions in bone metastasis.肿瘤-基质相互作用在骨转移中的作用。
Curr Osteoporos Rep. 2010 Jun;8(2):105-13. doi: 10.1007/s11914-010-0011-6.
8
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
9
[Identification of a new pro-invasion factor in tumor microenvironment: progress in function and mechanism of extracellular ATP].[肿瘤微环境中一种新的促侵袭因子的鉴定:细胞外ATP的功能与机制研究进展]
Beijing Da Xue Xue Bao Yi Xue Ban. 2017 Apr 18;49(2):188-195.
10
Prostate Epithelial RON Signaling Promotes M2 Macrophage Activation to Drive Prostate Tumor Growth and Progression.前列腺上皮细胞中的RON信号传导促进M2巨噬细胞活化,从而推动前列腺肿瘤的生长和进展。
Mol Cancer Res. 2020 Aug;18(8):1244-1254. doi: 10.1158/1541-7786.MCR-20-0060. Epub 2020 May 21.

引用本文的文献

1
Sensory innervation in the prostate and a role for calcitonin gene-related peptide in prostatic epithelial proliferation.前列腺中的感觉神经支配以及降钙素基因相关肽在前列腺上皮增殖中的作用。
Front Mol Neurosci. 2024 Dec 18;17:1497735. doi: 10.3389/fnmol.2024.1497735. eCollection 2024.
2
CRIPTO's multifaceted role in driving aggressive prostate cancer unveiled by in vivo, organoid, and patient data.体内、类器官和患者数据揭示CRIPTO在侵袭性前列腺癌发展中的多方面作用。
Oncogene. 2025 Mar;44(7):462-475. doi: 10.1038/s41388-024-03230-x. Epub 2024 Nov 26.
3
The role of NOP58 in prostate cancer progression through SUMOylation regulation and drug response.NOP58通过SUMO化修饰调控及药物反应在前列腺癌进展中的作用
Front Pharmacol. 2024 Oct 18;15:1476025. doi: 10.3389/fphar.2024.1476025. eCollection 2024.
4
Evidence of the Link between Stroma Remodeling and Prostate Cancer Prognosis.基质重塑与前列腺癌预后之间联系的证据。
Cancers (Basel). 2024 Sep 21;16(18):3215. doi: 10.3390/cancers16183215.
5
MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis.MDA-9/Syntenin 在肿瘤和微环境中定义了前列腺癌骨转移。
Proc Natl Acad Sci U S A. 2023 Nov 7;120(45):e2307094120. doi: 10.1073/pnas.2307094120. Epub 2023 Nov 3.
6
Cancer Stem Cells and Prostate Cancer: A Narrative Review.癌症干细胞与前列腺癌:叙事性综述。
Int J Mol Sci. 2023 Apr 24;24(9):7746. doi: 10.3390/ijms24097746.
7
Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value.碱性成纤维细胞生长因子在癌症中的作用:生物学活性、靶向治疗和预后价值。
Cells. 2023 Mar 24;12(7):1002. doi: 10.3390/cells12071002.
8
Liver Microenvironment Response to Prostate Cancer Metastasis and Hormonal Therapy.肝脏微环境对前列腺癌转移及激素治疗的反应
Cancers (Basel). 2022 Dec 15;14(24):6189. doi: 10.3390/cancers14246189.
9
A Nomogram for Predicting Prostate Cancer with Lymph Node Involvement in Robot-Assisted Radical Prostatectomy Era: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group).预测机器人辅助根治性前列腺切除术时代伴有淋巴结转移的前列腺癌的列线图:日本的一项回顾性多中心队列研究(MSUG94组)
Diagnostics (Basel). 2022 Oct 20;12(10):2545. doi: 10.3390/diagnostics12102545.
10
Prostate Cancer Tumor Stroma: Responsibility in Tumor Biology, Diagnosis and Treatment.前列腺癌肿瘤基质:在肿瘤生物学、诊断和治疗中的作用
Cancers (Basel). 2022 Sep 11;14(18):4412. doi: 10.3390/cancers14184412.

本文引用的文献

1
A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.一项评估阿柏西普(VEGF Trap)单药治疗复发性或转移性妇科癌肉瘤和子宫平滑肌肉瘤的 II 期临床研究。该研究由加拿大玛嘉烈公主癌症中心、美国芝加哥癌症协作组和加州癌症协作组共同开展。
Gynecol Oncol. 2012 Apr;125(1):136-40. doi: 10.1016/j.ygyno.2011.11.042. Epub 2011 Dec 2.
2
A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.一项评估 aflibercept 治疗晚期上皮性卵巢癌合并有症状恶性腹水患者的 II 期临床研究。
Gynecol Oncol. 2012 Apr;125(1):42-7. doi: 10.1016/j.ygyno.2011.11.021. Epub 2011 Nov 21.
3
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.达沙替尼联合多西他赛治疗去势抵抗性前列腺癌:来自 1-2 期研究的结果。
Cancer. 2012 Jan 1;118(1):63-71. doi: 10.1002/cncr.26204. Epub 2011 Jul 25.
4
The economic burden of prostate cancer.前列腺癌的经济负担。
BJU Int. 2011 Sep;108(6):806-13. doi: 10.1111/j.1464-410X.2011.10365.x.
5
Prostate cancer: evolution or revolution?
J Clin Oncol. 2011 Sep 20;29(27):3595-8. doi: 10.1200/JCO.2011.37.8653. Epub 2011 Aug 22.
6
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.癌症统计数据,2011 年:消除社会经济和种族差异对癌症过早死亡的影响。
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36. doi: 10.3322/caac.20121. Epub 2011 Jun 17.
7
Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者的生存获益
N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.
8
Immunotherapy for the treatment of prostate cancer.免疫疗法治疗前列腺癌。
Nat Rev Clin Oncol. 2011 May 24;8(9):551-61. doi: 10.1038/nrclinonc.2011.72.
9
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.复发性恶性脑胶质瘤中阿柏西普的 II 期研究:一项北美脑肿瘤联盟研究。
J Clin Oncol. 2011 Jul 1;29(19):2689-95. doi: 10.1200/JCO.2010.34.1636. Epub 2011 May 23.
10
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis.雄激素受体通过调节中心代谢和生物合成来促进前列腺癌的发展。
EMBO J. 2011 May 20;30(13):2719-33. doi: 10.1038/emboj.2011.158.